Want to join the conversation?
Biopharmaceutical company $GILD said the 48-week results from Study 1089, evaluating the safety and efficacy of switching virologically suppressed HIV-1 infected adult patients from F/TDF Truvada-based regimens to F/TAF-based regimens, showed improvements in renal and bone laboratory parameters in patients receiving F/TAF-based regimens.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.